The programmed cell death ligand-1 antibody, atezolizumab, is an immune checkpoint inhibitor approved for the treatment of various cancers. Herein, we describe a case of an 87-year-old man with advanced urothelial carcinoma. After surgery, atezolizumab was given. Subsequently, he developed generalized myasthenia gravis (MG) with elevated creatinine kinase and positive anti-striated muscle antibody. Although intravenous immunoglobulin was started, the patient developed cardiac arrhythmia and arrest. Our case not only reported MG as an immune-related adverse event of atezolizumab but also emphasized the significance of the programmed cell death-1 pathway in the pathogenesis of MG.
Immune checkpoint inhibition is a novel therapeutic strategy for several advanced cancers. Immune checkpoint inhibitors (ICIs) block the molecules which inactivate T-cells and enhance an immune response to tumor cells. On the other hand, by unleashing T cells ICIs can trigger immune-related adverse events (IRAEs) .
Atezolizumab is a fully humanized immunoglobulin monoclonal antibody that blocks the interaction of the programmed cell death ligand-1 (PD-L1) with the programmed cell death receptor-1 (PD-1) and CD80, which is one of the immune escape mechanisms of tumor cells. Atezolizumab has been approved for the treatment of advanced non-small cell lung cancer (NSCLC), urothelial carcinoma, triple-negative breast cancer and small cell lung cancer (SCLC) . Recently, various autoimmune conditions have been described with atezolizumab including colitis, hepatitis, pneumonitis, hypophysitis as well as autoimmune encephalitis [3-4].
Myasthenia gravis (MG) is an autoimmune disorder of neuromuscular junctions and usually manifests with fatigable weakness. It was reported in association with several ICIs including pembrolizumab, nivolumab, and ipilimumab . Herein, we described a case of new-onset MG in a patient treated with atezolizumab.
An 87-year-old Caucasian man with hypertension, dyslipidemia, and chronic kidney disease had recently been diagnosed with muscle-invasive urothelial carcinoma of the bladder. He underwent radical cystoprostatectomy and bilateral lymph node dissection. Subsequently, intravenous atezolizumab 1200 mg was given every three weeks.
After the second dose, he started having double vision and ptosis, followed by proximal muscle weakness and nasal voice which were worse with prolonged use. Despite being treated with prednisone 60 mg daily for seven days, the symptoms continued to progress. Therefore, he was transferred to our facility.
At presentation, vital signs were normal. Oxygen saturation at room air was 93%. He was alert and fully oriented. The cardiovascular and respiratory examinations were normal. Neurological examination showed severe external ophthalmoplegia and bilateral incomplete ptosis, which was improved after the placement of an instant cold pack. Neck flexion and extension powers were grade 4/5 and 5/5, respectively. The motor power in the four extremities was grade 3/5 for proximal and 4/5 for distal muscles. Deep tendon reflexes were normal. The sensory function was intact. Myasthenia gravis composite score was 17.
Laboratory studies showed elevated creatinine kinase (CK) at 1,542 U/L. C-reactive protein was 0.4 mg/dl. Antinuclear antibody, rheumatoid factor, cyclic citrulline peptide as well as, SS-A, SS-B, proteinase-3, and myeloperoxidase antibodies were negative. Electrocardiogram (ECG) showed a new right bundle branch block (RBBB) and left anterior fascicular block (Figure 1). Computed tomography of the chest showed no thymoma. Magnetic resonance imaging of the brain showed no stroke or brain metastasis.
Based on history, neurological syndrome on examination, lab findings, history of drug exposure, and exclusion of other confounding factors, the patient was diagnosed with new-onset Atezolizumab-induced class III MG based on the classification by the Myasthenia Gravis Foundation of America. Intravenous immunoglobulin (IVIG) 0.4 g/kg daily was started and planned to be given for five days. Low-dose oral pyridostigmine was later started. Muscle strength was improved after the administration of pyridostigmine as well.
Unfortunately, the patient developed cardiac arrest on the third day of admission. Complying with the patient's advanced directive, the family declined cardiopulmonary resuscitation. Prior to cardiac arrest, the patient had no sign of respiratory distress or chest pain. ECG monitoring showed occasional premature ventricular complexes and then asystole.
Later, the myasthenia and myositis antibodies panels were reported positive for an anti-striated muscle antibody at 1:40. Acetylcholine receptor (AChR)-blocking antibody was 21% inhibition. AChR binding and modulating antibodies were undetectable. muscle-specific tyrosine kinase and voltage-gated calcium channel antibodies were negative. All myositis antibodies were undetectable.
Immune checkpoints consist of various inhibitory pathways for the regulation of the immune system and the prevention of autoimmune disease. In many types of cancer, tumor cells hijack this inhibitory mechanism to escape the immune system. In current clinical practice, there are three classes of ICIs including Cytotoxic T lymphocyte-associated protein-4 (CTLA-4), PD-1, and PD-L1 inhibitors. These novel molecules have been approved for several cancers such as melanoma, NSCLC, renal cell carcinoma as well as urothelial cancer .
In the physiological state, CTLA-4 and PD-1 axes play a major role in the inhibition of autoreactive T cells. Polymorphisms of CTLA-4 and PD-1 are associated with various autoimmune diseases . In the tumor environment, these molecules are overexpressed and inhibit the immune response as well . The blockade of these proteins reactivates cytotoxic T cells to destroy tumor cells. However, unbalancing the immune system by blocking immune checkpoints favors the development of autoimmune disorders.
CTLA-4 and PD-1 inhibitors, as well as their combinations, have been reported to trigger both new onset and exacerbation of MG with a significantly high mortality rate . As compared to cases of idiopathic MG, concomitant myositis and myocarditis, as well as mortality, were significantly higher in ICI-induced MG .
Atezolizumab was previously reported with exacerbation of MG which complicated with hypercapnic respiratory failure and required intubation . Our case is the first reported case of atezolizumab-related new onset MG. Elevation of serum CK, as seen in our case, is frequent in ICI-associated MG and may indicate concomitant myositis . New RBBB with left anterior fascicular block and progressive cardiac arrhythmia prior to cardiac arrest raised the possibility of myocardium involvement. However, confirmation of muscle and myocardium involvement by autopsy was not performed according to the family’s wish.
In MG, the prior study showed significant overexpression of PD-1 on CD4+ T cells and PD-L1 on CD14+monocytes . Moreover, overexpression of PD-L1 on muscle cells of MG patients was reported with a unimodal relationship with severity, measured by Quantitative myasthenia gravis score . This case report demonstrated an MG causing by the blockage of the interaction between PD-1 and PD-L1 in human. These findings highlighted the regulatory role of the PD-1/PD-L1 pathway in the pathogenesis of MG. However, more studies are needed to understand the role of the PD-1/PD-L1 pathway in MG.
ICIs are the novel therapeutic agents for cancers. On the other hand, these agents can trigger IRAEs. Our case highlights de novo MG as a severe IRAE of atezolizumab. As in the presented case, the previous case reports suggested that concomitant myositis and myocarditis are common in ICI-induced MG. Moreover, MG induced by ICIs is usually severe and associates with high mortality. Furthermore, our case provides further evidence for the functional significance of the PD-1/PD-L1 pathway in the pathogenesis of MG.
- Michot JM, Bigenwald C, Champiat S, et al.: Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016, 54:139-148. 10.1016/j.ejca.2015.11.016
- Tecentriq: the first FDA-approved anti-PDL1 cancer immunotherapy. (2019). Accessed: June 5, 2019: https://www.tecentriq-hcp.com/..
- Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, Korenstein D: Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018, 360:k793. 10.1136/bmj.k793
- Levine JJ, Somer RA, Hosoya H, Squillante C: Atezolizumab-induced encephalitis in metastatic bladder cancer: a case report and review of the literature. Clin Genitourin Cancer. 2017, 15:e847-e849. 10.1016/j.clgc.2017.03.001
- Makarious D, Horwood K, Coward JIG: Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017, 82:128-136. 10.1016/j.ejca.2017.05.041
- Park YJ, Kuen DS, Chung Y: Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. Exp Mol Med. 2018, 50:109. 10.1038/s12276-018-0130-1
- Seidel JA, Otsuka A, Kabashima K: Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018, 8:86. 10.3389/fonc.2018.00086
- Suzuki S, Ishikawa N, Konoeda F, et al.: Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017, 89:1127-1134. 10.1212/wnl.0000000000004359
- Chae J, Peikert T: Myasthenia gravis crisis complicating anti-PD-L1 cancer immunotherapy. Crit Care Med. 2018, 46:280. 10.1097/01.ccm.0000528605.84679.eb
- Sakthivel P, Ramanujam R, Wang XB, Pirskanen R, Lefvert AK: Programmed death- 1: from gene to protein in autoimmune human myasthenia gravis. J Neuroimmunol. 2008, 193:149-155.
- Iwasa K, Yoshikawa H, Furukawa Y, Yamada M: Programmed cell death ligand 1 expression is upregulated in the skeletal muscle of patients with myasthenia gravis. J Neuroimmunol. 2018, 325:74-78. 10.1016/j.jneuroim.2018.09.012
De Novo Myasthenia Gravis Induced by Atezolizumab in a Patient with Urothelial Carcinoma
Ethics Statement and Conflict of Interest Disclosures
Human subjects: Consent was obtained by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Cite this article as:
Thakolwiboon S, Karukote A, Wilms H (June 25, 2019) De Novo Myasthenia Gravis Induced by Atezolizumab in a Patient with Urothelial Carcinoma. Cureus 11(6): e5002. doi:10.7759/cureus.5002
Received by Cureus: June 09, 2019
Peer review began: June 14, 2019
Peer review concluded: June 17, 2019
Published: June 25, 2019
© Copyright 2019
Thakolwiboon et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.